Curevac News

At the end of the latest market close, CureVac N.V. (CVAC) was valued at $49.89. In that particular session, Stock kicked-off at the price of $52.42 while reaching the peak value of $56.13 and lowest value recorded on the day was $52.25. The stock current value is $54.54.Recently in News on June 30, 2021, CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60. – Unique pivotal study conducted in 10 countries in fast changing variant environment; 15 COVID-19 variant strains present for efficacy analysis; original strain almost completely absent- Statistical success criteria for primary endpoint met on basis of 228 adjudicated cases- Vaccine efficacy of 48% against COVID-19 of any severity across all age groups and 15 variants- Significant vaccine efficacy demonstrated in participants aged 18 to 60 and across all 15 variants:- Efficacy of 53% against disease of any severity- Efficacy of 77% against moderate and severe disease- Full protection against hospitalization or death- CureVac in ongoing dialogue with EMA; continuing regulatory submission. You can read further details here

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CureVac N.V. shares are logging -64.07% during the 52-week period from high price, and 50.87% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $36.15 and $151.80.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


>

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1204017 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CureVac N.V. (CVAC) recorded performance in the market was -32.72%, having the revenues showcasing -50.02% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 10.71B, as it employees total of 500 workers.

>

CureVac N.V. (CVAC) in the eye of market guru’s

During the last month, 2 analysts gave the CureVac N.V. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 88.19, with a change in the price was noted -32.06. In a similar fashion, CureVac N.V. posted a movement of -37.02% for the period of last 100 days, recording 1,243,061 in trading volumes.

>

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CVAC is recording 0.08 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.07.

>> 7 Top Picks for the Post-Pandemic Economy

CureVac N.V. (CVAC): Stocks Technical analysis and Trends

Raw Stochastic average of CureVac N.V. in the period of last 50 days is set at 9.45%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 51.07%. In the last 20 days, the company’s Stochastic %K was 22.01% and its Stochastic %D was recorded 14.90%.

If we look into the earlier routines of CureVac N.V., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -32.72%. The shares increased approximately by 4.14% in the 7-day charts and went up by -15.78% in the period of the last 30 days. Common stock shares were lifted by -50.02% during last recorded quarter.

Source : https://investchronicle.com/2021/08/04/curevac-n-v-cvac-market-price-of-54-54-offers-the-impression-of-an-exciting-value-play/

870
CureVac N.V. (CVAC) market price of $54.54 offers the impression of an exciting value play

Source:investchronicle

CureVac N.V. (CVAC) market price of $54.54 offers the impression of an exciting value play

CureVac NV (CVAC): Price Now Near $50.49; Daily Chart Shows Downtrend on 50 Day Basis

Source:ETF Daily News

CureVac NV (CVAC): Price Now Near $50.49; Daily Chart Shows Downtrend on 50 Day Basis

We Might See A Profit From CureVac N.V. (NASDAQ:CVAC) Soon

Source:Nasdaq

We Might See A Profit From CureVac N.V. (NASDAQ:CVAC) Soon

Pfizer Stock – CureVac COVID-19 vaccine records only 48% efficacy in final trial readout

Source:fintechzoom

Pfizer Stock – CureVac COVID-19 vaccine records only 48% efficacy in final trial readout

Novartis set to deliver 50 mln CureVac COVID-19 vaccines this year

Source:Reuters

Novartis set to deliver 50 mln CureVac COVID-19 vaccines this year

Novartis set to deliver 50 million CureVac COVID-19 vaccines this year

Source:Yahoo News

Novartis set to deliver 50 million CureVac COVID-19 vaccines this year